Cargando…
BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study
BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161128/ https://www.ncbi.nlm.nih.gov/pubmed/32293279 http://dx.doi.org/10.1186/s12872-020-01439-8 |
_version_ | 1783522895499100160 |
---|---|
author | Awad, Khaled Weiss, Raul Yunus, Asim Bittrick, Jon M. Nekkanti, Rajasekhar Houmsse, Mahmoud Okabe, Toshimasa Adamson, Teagan Miller, Crystal Alawwa, Abdul K. |
author_facet | Awad, Khaled Weiss, Raul Yunus, Asim Bittrick, Jon M. Nekkanti, Rajasekhar Houmsse, Mahmoud Okabe, Toshimasa Adamson, Teagan Miller, Crystal Alawwa, Abdul K. |
author_sort | Awad, Khaled |
collection | PubMed |
description | BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support. METHODS: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected. RESULTS: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]). CONCLUSIONS: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations. TRIAL REGISTRATION: clinicaltrials.gov, NCT02756338. Registered 29 April 2016. |
format | Online Article Text |
id | pubmed-7161128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71611282020-04-22 BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study Awad, Khaled Weiss, Raul Yunus, Asim Bittrick, Jon M. Nekkanti, Rajasekhar Houmsse, Mahmoud Okabe, Toshimasa Adamson, Teagan Miller, Crystal Alawwa, Abdul K. BMC Cardiovasc Disord Research Article BACKGROUND: Insertable cardiac monitors are utilized for the diagnosis of arrhythmias and traditionally have been inserted within hospitals. Recent code updates allow for reimbursement of office-based insertions; however, there is limited information regarding the resources and processes required to support in-office insertions. We sought to determine the safety and feasibility of in-office insertion of the BioMonitor 2 and better understand in-office procedures, including patient selection, pre-insertion protocols, resource availability, and staff support. METHODS: Patients meeting an indication for a rhythm monitor were prospectively enrolled into this single-arm, non-randomized trial. All patients underwent insertion in an office setting. Two follow-up visits at days 7 and 90 were required. Information on adverse events, device performance, office site preparations, and resource utilization were collected. RESULTS: Eighty-two patients were enrolled at six sites. Insertion was successful in all 77 patients with an attempt. Oral anticoagulation was stopped in 20.8% of patients and continued through insertion in 23.4%, while prophylactic antibiotics were infrequently utilized (37.7% of study participants). On average, the procedure required a surgeon plus two support staff and 35 min in an office room to complete the 8.4 min insertion procedure. The mean R-wave amplitude was 0.77 mV at insertion and 0.67 mV at 90-days with low noise burden (2.7%). There were no procedure related complications. Two adverse events were reported (event rate 2.7% [95% CI 0.3, 9.5%]). CONCLUSIONS: In-office insertion of the BioMonitor 2 is safe and feasible. Devices performed well with high R-wave amplitudes and low noise burden. These results further support shifting cardiac monitor insertions to office-based locations. TRIAL REGISTRATION: clinicaltrials.gov, NCT02756338. Registered 29 April 2016. BioMed Central 2020-04-15 /pmc/articles/PMC7161128/ /pubmed/32293279 http://dx.doi.org/10.1186/s12872-020-01439-8 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Awad, Khaled Weiss, Raul Yunus, Asim Bittrick, Jon M. Nekkanti, Rajasekhar Houmsse, Mahmoud Okabe, Toshimasa Adamson, Teagan Miller, Crystal Alawwa, Abdul K. BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title | BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title_full | BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title_fullStr | BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title_full_unstemmed | BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title_short | BioMonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort BioInsight study |
title_sort | biomonitor 2 in-office setting insertion safety and feasibility evaluation with device functionality assessment: results from the prospective cohort bioinsight study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7161128/ https://www.ncbi.nlm.nih.gov/pubmed/32293279 http://dx.doi.org/10.1186/s12872-020-01439-8 |
work_keys_str_mv | AT awadkhaled biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT weissraul biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT yunusasim biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT bittrickjonm biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT nekkantirajasekhar biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT houmssemahmoud biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT okabetoshimasa biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT adamsonteagan biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT millercrystal biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy AT alawwaabdulk biomonitor2inofficesettinginsertionsafetyandfeasibilityevaluationwithdevicefunctionalityassessmentresultsfromtheprospectivecohortbioinsightstudy |